JP2020535832A - マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 - Google Patents
マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 Download PDFInfo
- Publication number
- JP2020535832A JP2020535832A JP2020519092A JP2020519092A JP2020535832A JP 2020535832 A JP2020535832 A JP 2020535832A JP 2020519092 A JP2020519092 A JP 2020519092A JP 2020519092 A JP2020519092 A JP 2020519092A JP 2020535832 A JP2020535832 A JP 2020535832A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- tcr
- mtcr
- antibody
- amplification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 112
- 210000004027 cell Anatomy 0.000 claims abstract description 343
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 169
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 71
- 239000000427 antigen Substances 0.000 claims abstract description 68
- 102000036639 antigens Human genes 0.000 claims abstract description 67
- 108091007433 antigens Proteins 0.000 claims abstract description 67
- 201000011510 cancer Diseases 0.000 claims abstract description 49
- 102000004127 Cytokines Human genes 0.000 claims abstract description 11
- 108090000695 Cytokines Proteins 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 108010002350 Interleukin-2 Proteins 0.000 claims description 36
- 102000000588 Interleukin-2 Human genes 0.000 claims description 36
- 201000010099 disease Diseases 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 241000124008 Mammalia Species 0.000 claims description 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 230000003612 virological effect Effects 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 11
- 108010074108 interleukin-21 Proteins 0.000 claims description 9
- 230000000735 allogeneic effect Effects 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 6
- 102000003812 Interleukin-15 Human genes 0.000 claims description 4
- 108090000172 Interleukin-15 Proteins 0.000 claims description 4
- 239000012636 effector Substances 0.000 claims description 4
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 108091033409 CRISPR Proteins 0.000 claims description 2
- 238000010354 CRISPR gene editing Methods 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 101710163270 Nuclease Proteins 0.000 claims description 2
- 239000004234 Yellow 2G Substances 0.000 claims description 2
- 239000002151 riboflavin Substances 0.000 claims description 2
- 230000002103 transcriptional effect Effects 0.000 claims description 2
- 108091081548 Palindromic sequence Proteins 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 238000010586 diagram Methods 0.000 abstract description 9
- 230000003321 amplification Effects 0.000 description 122
- 238000003199 nucleic acid amplification method Methods 0.000 description 122
- 108091008874 T cell receptors Proteins 0.000 description 91
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 85
- 241000699666 Mus <mouse, genus> Species 0.000 description 49
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 47
- 238000004520 electroporation Methods 0.000 description 30
- 108090000765 processed proteins & peptides Proteins 0.000 description 30
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 28
- 239000013612 plasmid Substances 0.000 description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 21
- 239000000872 buffer Substances 0.000 description 18
- 239000013642 negative control Substances 0.000 description 18
- 230000035755 proliferation Effects 0.000 description 17
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 13
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 12
- 102100034893 E3 ubiquitin-protein ligase HUWE1 Human genes 0.000 description 12
- 101001019732 Homo sapiens E3 ubiquitin-protein ligase HUWE1 Proteins 0.000 description 12
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 12
- 210000000265 leukocyte Anatomy 0.000 description 12
- 101100096028 Mus musculus Smok1 gene Proteins 0.000 description 10
- 102000008579 Transposases Human genes 0.000 description 10
- 108010020764 Transposases Proteins 0.000 description 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 9
- 102100037850 Interferon gamma Human genes 0.000 description 9
- 108010074328 Interferon-gamma Proteins 0.000 description 9
- 230000002072 anti-mutant effect Effects 0.000 description 9
- 239000011324 bead Substances 0.000 description 8
- 238000003501 co-culture Methods 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 102100029987 Erbin Human genes 0.000 description 7
- 101001010810 Homo sapiens Erbin Proteins 0.000 description 7
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 7
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000009258 tissue cross reactivity Effects 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108010069941 DNA receptor Proteins 0.000 description 4
- 101100502152 Mus musculus F5 gene Proteins 0.000 description 4
- 230000006052 T cell proliferation Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
- 229960004528 vincristine Drugs 0.000 description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108700031361 Brachyury Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100038078 CD276 antigen Human genes 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241001272567 Hominoidea Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 240000007019 Oxalis corniculata Species 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 241001493546 Suina Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010062746 Carditis Diseases 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000699679 Cricetulus migratorius Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 102100030708 GTPase KRas Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241001663880 Gammaretrovirus Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010038707 Respiratory papilloma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000032383 Soft tissue cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 102100039094 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 208000021646 inflammation of heart layer Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 208000014899 intrahepatic bile duct cancer Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 201000003956 middle ear cancer Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 201000003437 pleural cancer Diseases 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- -1 rituximab Chemical compound 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000004149 tartrazine Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464448—Regulators of development
- A61K39/46445—Apoptosis related proteins, e.g. survivin or livin
- A61K39/464451—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464491—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/28—Expressing multiple CARs, TCRs or antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2312—Interleukin-12 (IL-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023220106A JP2024050551A (ja) | 2017-10-05 | 2023-12-26 | マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762568339P | 2017-10-05 | 2017-10-05 | |
| US62/568,339 | 2017-10-05 | ||
| PCT/US2018/052432 WO2019070435A1 (en) | 2017-10-05 | 2018-09-24 | METHODS FOR SELECTIVE EXPANSION OF CELLS EXPRESSING A TCR WITH A CONSTANT MURINE REGION |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023220106A Division JP2024050551A (ja) | 2017-10-05 | 2023-12-26 | マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020535832A true JP2020535832A (ja) | 2020-12-10 |
| JP2020535832A5 JP2020535832A5 (es) | 2021-11-04 |
Family
ID=63841049
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020519092A Pending JP2020535832A (ja) | 2017-10-05 | 2018-09-24 | マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 |
| JP2023220106A Pending JP2024050551A (ja) | 2017-10-05 | 2023-12-26 | マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023220106A Pending JP2024050551A (ja) | 2017-10-05 | 2023-12-26 | マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200254018A1 (es) |
| EP (2) | EP4269595A3 (es) |
| JP (2) | JP2020535832A (es) |
| KR (1) | KR20200064107A (es) |
| CN (1) | CN111417720A (es) |
| AU (1) | AU2018345400A1 (es) |
| CA (1) | CA3077595A1 (es) |
| ES (1) | ES2960313T3 (es) |
| FI (1) | FI3692140T3 (es) |
| IL (1) | IL273698A (es) |
| MA (1) | MA50748A (es) |
| SG (1) | SG11202003112QA (es) |
| WO (1) | WO2019070435A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022183167A1 (en) | 2021-02-25 | 2022-09-01 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| WO2023150562A1 (en) * | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11512284A (ja) * | 1995-09-05 | 1999-10-26 | ザ ジェネラル ホスピタル コーポレイション | 単クローン性リンパ球及び利用方法 |
| JP2003276960A (ja) * | 2002-03-26 | 2003-10-02 | Mitsubishi Electric Corp | エレベーター制御システム |
| JP2008253267A (ja) * | 1991-12-13 | 2008-10-23 | Xoma Technology Ltd | 改変抗体可変領域の調製のための物質ならびにその治療的用途 |
| WO2016053339A1 (en) * | 2014-10-02 | 2016-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cells having antigenic specificity for a cancer-specific mutation |
| JP2016527230A (ja) * | 2013-07-15 | 2016-09-08 | アメリカ合衆国 | 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体 |
| JP2017524372A (ja) * | 2014-05-29 | 2017-08-31 | アメリカ合衆国 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2602145T3 (es) | 2002-09-06 | 2017-02-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inmunoterapia con linfocitos específicos de antígeno seleccionados in vitro después de quimioterapia supresora de linfocitos no mieloablativa |
| US8772451B2 (en) * | 2003-11-10 | 2014-07-08 | Altor Bioscience Corporation | Soluble TCR molecules and methods of use |
| CA2651174A1 (en) * | 2006-05-03 | 2007-11-15 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Chimeric t cell receptors and related materials and methods of use |
| US8216565B2 (en) | 2007-01-12 | 2012-07-10 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | GP100-specific T cell receptors and related materials and methods of use |
| US8785601B2 (en) | 2009-01-28 | 2014-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors and related materials and methods of use |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| CN103124740B (zh) | 2010-09-21 | 2015-09-02 | 美国卫生和人力服务部 | 抗-ssx-2t细胞受体和相关材料及使用方法 |
| WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| EP2852613B1 (en) | 2012-05-22 | 2019-01-23 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Murine anti-ny-eso-1 t cell receptors |
| CA2884743C (en) * | 2012-09-14 | 2023-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing mhc class ii-restricted mage-a3 |
| CA2968457C (en) * | 2014-11-20 | 2023-12-05 | Umc Utrecht Holding B.V. | Use of antibodies for enrichment of engineered t cells with exogenous immune receptors and antibodies for use in depletion of engineered t cells |
-
2018
- 2018-09-24 MA MA050748A patent/MA50748A/fr unknown
- 2018-09-24 EP EP23185846.5A patent/EP4269595A3/en active Pending
- 2018-09-24 EP EP18786145.5A patent/EP3692140B1/en active Active
- 2018-09-24 JP JP2020519092A patent/JP2020535832A/ja active Pending
- 2018-09-24 AU AU2018345400A patent/AU2018345400A1/en active Pending
- 2018-09-24 WO PCT/US2018/052432 patent/WO2019070435A1/en active Application Filing
- 2018-09-24 ES ES18786145T patent/ES2960313T3/es active Active
- 2018-09-24 KR KR1020207012314A patent/KR20200064107A/ko unknown
- 2018-09-24 US US16/652,948 patent/US20200254018A1/en active Pending
- 2018-09-24 FI FIEP18786145.5T patent/FI3692140T3/fi active
- 2018-09-24 CN CN201880076862.9A patent/CN111417720A/zh active Pending
- 2018-09-24 SG SG11202003112QA patent/SG11202003112QA/en unknown
- 2018-09-24 CA CA3077595A patent/CA3077595A1/en active Pending
-
2020
- 2020-03-30 IL IL273698A patent/IL273698A/en unknown
-
2023
- 2023-12-26 JP JP2023220106A patent/JP2024050551A/ja active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008253267A (ja) * | 1991-12-13 | 2008-10-23 | Xoma Technology Ltd | 改変抗体可変領域の調製のための物質ならびにその治療的用途 |
| JPH11512284A (ja) * | 1995-09-05 | 1999-10-26 | ザ ジェネラル ホスピタル コーポレイション | 単クローン性リンパ球及び利用方法 |
| JP2003276960A (ja) * | 2002-03-26 | 2003-10-02 | Mitsubishi Electric Corp | エレベーター制御システム |
| JP2016527230A (ja) * | 2013-07-15 | 2016-09-08 | アメリカ合衆国 | 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体 |
| JP2017524372A (ja) * | 2014-05-29 | 2017-08-31 | アメリカ合衆国 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
| WO2016053339A1 (en) * | 2014-10-02 | 2016-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cells having antigenic specificity for a cancer-specific mutation |
| JP2017535253A (ja) * | 2014-10-02 | 2017-11-30 | アメリカ合衆国 | がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法 |
Non-Patent Citations (1)
| Title |
|---|
| MOLECULAR THERAPY, 2016, VOL.24, NO.6, PP.1078-1089, JPN6022035564, ISSN: 0004995494 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024050551A (ja) | 2024-04-10 |
| ES2960313T3 (es) | 2024-03-04 |
| EP3692140A1 (en) | 2020-08-12 |
| IL273698A (en) | 2020-05-31 |
| EP3692140B1 (en) | 2023-07-19 |
| KR20200064107A (ko) | 2020-06-05 |
| WO2019070435A1 (en) | 2019-04-11 |
| WO2019070435A8 (en) | 2020-01-30 |
| FI3692140T3 (fi) | 2023-10-11 |
| SG11202003112QA (en) | 2020-05-28 |
| CA3077595A1 (en) | 2019-04-11 |
| EP4269595A3 (en) | 2023-12-06 |
| CN111417720A (zh) | 2020-07-14 |
| EP4269595A2 (en) | 2023-11-01 |
| US20200254018A1 (en) | 2020-08-13 |
| MA50748A (fr) | 2020-08-12 |
| AU2018345400A1 (en) | 2020-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7162530B2 (ja) | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 | |
| ES2891578T3 (es) | Antígeno quimérico y receptores de células T y métodos de uso | |
| JP7048494B2 (ja) | 修飾ｔ細胞に対する条件的活性型キメラ抗原受容体 | |
| JP7280827B2 (ja) | Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法 | |
| JP2023038386A (ja) | 細胞免疫療法のための方法および組成物 | |
| US20190375815A1 (en) | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities | |
| JP7118887B2 (ja) | 最適化されたレンチウイルス移入ベクターおよびその使用 | |
| BR112020007710A2 (pt) | métodos para produzir células que expressam receptor de antígeno quimérico | |
| CN112955465A (zh) | 抗tcr抗体分子及其用途 | |
| JP7064663B2 (ja) | Ｉｌ－１３ｒａ２を標的とする抗体及びその応用 | |
| JP2024050551A (ja) | マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 | |
| KR20230129983A (ko) | 조작된 세포 요법을 위한 표적화된 사이토카인 구축물 | |
| TW201930589A (zh) | 表現特異性辨識人類間皮素之細胞表面分子、il-7、及ccl19之免疫活性細胞 | |
| AU2021310467A1 (en) | Chimeric molecules providing targeted costimulation for adoptive cell therapy | |
| JP2021536256A (ja) | 修飾ｔ細胞に対する条件的活性型キメラ抗原受容体 | |
| WO2021164753A1 (en) | Methods and compositions for modulating arginine levels in immune cells | |
| US11697677B2 (en) | Chimeric molecules providing targeted costimulation for adoptive cell therapy | |
| JP2021534784A (ja) | Ｂ７ｈ３キメラ抗原受容体を含む方法および組成物 | |
| JP2015092865A (ja) | ヒト化抗ｃｄ２０キメラ抗原レセプター | |
| US20230019849A1 (en) | Method for Preparing CD7-Negative, CD3-Positive T Cells | |
| EP4370543A1 (en) | T cell receptors (tcr) to human papillomavirus proteins, compositions, and uses thereof | |
| AU2022226655A1 (en) | Codon-optimized nucleotide sequences encoding an ap-1 transcription factor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20200827 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200827 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210924 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210924 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220812 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220830 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221130 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230221 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230522 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230720 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230829 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231226 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240104 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20240308 |